Sawai Pharmaceutical's First Quarter Profit Doubles
This article was originally published in PharmAsia News
Japan's largest generic drug maker Sawai Pharmaceutical announced Aug. 7 positive results for the quarter. Company profit doubled to ¥1.85 billion compared to the same period last year. Sawai cited the further expanding generic drug market in Japan stimulated by the government policy to constrain medical cost growth, and a May market launch for new products instead of July in last year's case. The company's share price jumped due to the news. (Click here for more - Japanese language
You may also be interested in...
With some studies about to finish and others on clinical hold, the coronavirus vaccine field approaches an infection point as the US FDA prepares for its first advisory committee on the topic. Our charts and graphics offer a quick look at what stands where.
Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.
RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.